您好,欢迎访问三七文档
当前位置:首页 > 医学/心理学 > 药学 > WHO第961号技术报告-附件7-药物生产技术转移指南(中英文)
WHO第961号技术报告附件7药物生产技术转移指南(中英文1/4)2013-09-2914:16:27|分类:WHO|字号订阅WorldHealthOrganizationWHOTechnicalReportSeries,No.961,2011WHO第961号技术报告附件7药物生产技术转移指南Annex7附件7WHOguidelinesontransferoftechnologyinpharmaceuticalmanufacturingWHO药物生产技术转移指南1.Introduction介绍2.Scope范围3.Glossary术语4.Organizationandmanagement组织和管理5.Production:transfer(processing,packagingandcleaning)生产:转移(工艺、包装和清洁)6.Qualitycontrol:analyticalmethodtransfer质量控制:分析方法转移7.Premisesandequipment厂房设施和设备8.Documentation文件9.Qualificationandvalidation确认和验证References参考文献1.Introduction介绍Theseguidingprinciplesontransferoftechnologyareintendedtoserveasaframeworkwhichcanbeappliedinaflexiblemannerratherthanasstrictrigidguidance.Focushasbeenplacedonthequalityaspects,inlinewithWHO’smandate.本指南中关于技术转移的原则意在作为一个框架,以不同方式应用,而不是一个需要严格遵守的指南。指南重点在于质量方面,与WHO的任务一致。1.1Transferofprocessestoanalternativesiteoccursatsomestageinthelife-cycleofmostproducts,fromdevelopment,scale-up,manufacturing,productionandlaunch,tothepost-approvalphase.将工艺转移至一个可替代的场所发生在大多数产品的生命周期的某些阶段,从研发、放大、生产、到上市后阶段。1.2Transferoftechnologyisdefinedas“alogicalprocedurethatcontrolsthetransferofanyprocesstogetherwithitsdocumentationandprofessionalexpertisebetweendevelopmentandmanufactureorbetweenmanufacturesites”.Itisasystematicprocedurethatisfollowedinordertopassthedocumentedknowledgeandexperiencegainedduringdevelopmentandorcommercializationtoanappropriate,responsibleandauthorizedparty.技术转移被定义为“控制研发方和生产方,或两个生产场所之间所有工艺关其文件和专业技术转移的逻辑程序”。技术转移是一个系统性的程序,遵守该程序是为了能将在研发过程中已记录的知识和经验转移给一个适当的,承担责任的经过授权的主体方。Technologytransferembodiesboththetransferofdocumentationandthedemonstratedabilityofthereceivingunit(RU)toeffectivelyperformthecriticalelementsofthetransferredtechnology,tothesatisfactionofallpartiesandanyapplicableregulatorybodies.技术转移包括文件转移和接收单位的重现能力,以使用得转移技术的关键要素得以有效实施,满足参与各方和所有适用法规的要求。1.3Literaturesearchesrevealedlittleinformationonthesubjectoriginatingfromnationalorregionalregulatorybodies.GuidanceonintracompanytransferswaspreparedbytheInternationalSocietyforPharmaceuticalEngineering(ISPE)(1).文献查阅显示来自于国家或地区药监部门关于本主题的信息非常少。ISPE(I)有一份关于跨公司转移指南。1.4Theeverchangingbusinessstrategiesofpharmaceuticalcompaniesincreasinglyinvolveintra-andintercompanytransfersoftechnologyforreasonssuchastheneedforadditionalcapacity,relocationofoperationsorconsolidationsandmergers.TheWHOExpertCommitteeonSpecificationsforPharmaceuticalPreparations,therefore,recommendedinitsfortysecondreportthatWHOaddressthisissuethroughpreparationofWHOguidelinesonthismatter(2).制药企业的经营策略导致在公司间、公司内进行技术转移日益增加,原因各种各样,例如增加产能的需求、寻求新的生产场所、合并和收购。因此,WHO制剂质量标准专家委员会在WHO第42期报告中对制剂的WHO指南中阐述了对此问题的推荐。1.5Transferoftechnologyrequiresadocumented,plannedapproachusingtrainedandknowledgeablepersonnelworkingwithinaqualitysystem,withdocumentationofdatacoveringallaspectsofdevelopment,productionandqualitycontrol.Usuallythereisasendingunit(SU),areceivingunitandtheunitmanagingtheprocess,whichmayormaynotbeaseparateentity.For“contractmanufacturing”pleaseseegoodmanufacturingpractices(GMP)(3).技术转移需要一种记录的计划方式,人员应经过培训、有知识背景,在一个质量体系下工作,数据记录应覆盖研发、和平和质量控制各方面。一般会有一个转出方(SU),一个接收方和管理工艺的单位。管理工艺的单位可以是一个独立的主体,也可不是。关于“合同制造”,请参见GMP(3)。1.6Forthetransfertobesuccessful,thefollowinggeneralprinciplesandrequirementsshouldbemet:为使转移成功,应符合以下一般原则和要求theprojectplanshouldencompassthequalityaspectsoftheprojectandbebasedupontheprinciplesofqualityriskmanagement;项目计划应基于质量风险管理,对项目的质量方面起到指导作用,thecapabilitiesoftheSUandattheRUshouldbesimilar,butnotnecessarilyidentical,andfacilitiesandequipmentshouldoperateaccordingtosimilaroperatingprinciples;接收单位和转出单位的产能应相似,但不是必须的,设施和设备应根据相似的操作原则进行操作acomprehensivetechnicalgapanalysisbetweentheSUandRUincludingtechnicalriskassessmentandpotentialregulatorygaps,shouldbeperformedasneeded;如有需要,应对转出单位和接收单位进行综合技术差异分析,包括技术风险评估和潜在法规差异adequatelytrainedstaffshouldbeavailableorshouldbetrainedattheRU:接收单位应具有经过充分培训地员工,或培训其员工—regulatoryrequirementsinthecountriesoftheSUandtheRU,andinanycountrieswheretheproductisintendedtobesupplied,shouldbetakenintoaccountandinterpretedconsistentlythroughoutanytransferprogrammeproject;and—接收单位和转出单位的所在国法规要求,以及任何该产品将要销售的国家的法规要求,均应进行考虑,并在整个转移程序项目期间有一致的解释—thereshouldbeeffectiveprocessandproductknowledgetransfer.—工艺和产品知识转移应有效果1.7TechnologytransfercanbeconsideredsuccessfulifthereisdocumentedevidencethattheRUcanroutinelyreproducethetransferredproduct,processormethodagainstapredefinedsetofspecificationsasagreedwiththeSU.如果有文件化的证据证明接收单位可以正常地再次生产出所转移的产品、工艺或方法,使用其符合与转出单位协商同意的一系列既定的规格,则可以认为技术转移已经成功。1.8IntheeventthattheRUidentifiesparticularproblemswiththeprocessduringthetransfer,theRUshouldcommunicatethembacktotheSUtoensurecontinuingknowledgemanagement.如果接收单位在转移过程中发现工艺有一些特别的问题,应反馈回转出单位,以保证继续进行知识管理。1.9Technologytransferprojects,particularlythosebetweendifferentcompanies,havelegalandeconomicimplications.Ifsuchissues,whichmayincludeintellectualpropertyrights,royalties,pricing,conflictofinterestandconfidentiality,areexpectedtoimpactonopencommunicationoftechnicalmattersinanyway,theyshouldbeaddressedbeforeandduringplanningandexecutionofthetransfer.技术转移项目,是那些不同公司间转移的项目,牵涉到法律和经济方面。如果这些方面,可能会包括知
本文标题:WHO第961号技术报告-附件7-药物生产技术转移指南(中英文)
链接地址:https://www.777doc.com/doc-5124719 .html